Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-11337939-B2
Publication Date
2022-05-24
Expiration Date
Abstract
A method for treating patients with COVID-19 and/or other respiratory conditions include administering a dosage of 75-100 milligrams of dapsone twice daily. A variety of dapsone formulation and delivery devices are disclosed, including an inhaler, nasal spray, nasal gel, otic formulation, intravenous formulation, oral solution, oral suspension, patch and suppository.
Core Innovation
The invention relates to suppressing an autoimmune reaction to COVID-19 in a person afflicted with COVID-19 by administering an effective dosage of dapsone. The disclosure further addresses acute respiratory distress syndrome and respiratory inflammatory complications associated with COVID-19, including immune-related conditions described as cytokine-storm related. Dapsone is identified as 4,4′-diaminodiphenyl sulfone (DDS).
The problem described in the background is the treatment of COVID-19 and respiratory inflammatory complications, including conditions associated with immune dysregulation such as cytokine storm, in a way that suppresses an autoimmune reaction in afflicted persons. The disclosure positions dapsone administration as a means to provide antimicrobial, anti-inflammatory, and immune-modulatory activity in the context of COVID-19 and related respiratory inflammatory disorders.
The disclosure also provides multiple dapsone delivery formats for respiratory use and other delivery routes, including inhaler apparatus, nasal spray or nasal gel or nasal drops, otic formulations, intravenous formulations, oral solutions and suspensions, and transdermal slow/fast-release patches and suppositories. Inhaler delivery includes micronized powder or liquid solution, and respiratory formulations may optionally include antibiotics such as azithromycin and/or doxycycline.
Claims Coverage
The independent claim is directed to a method of suppressing an autoimmune reaction to COVID-19 by administering an effective dosage of dapsone. The inventive features include dosage range, twice-daily dosing, treatment duration, and administration routes such as nasal spray and inhaler apparatus, with some refinements including azithromycin and doxycycline.
Suppressing an autoimmune reaction to COVID-19 with dapsone
A method of suppressing an autoimmune reaction to COVID-19 in a person afflicted with COVID-19 comprising administering an effective dosage of dapsone to the person.
Twice-daily dapsone dosage range
Administering an effective dosage of dapsone to the person includes giving 75–100 milligrams of dapsone twice per day.
Twenty-one day dapsone course
Administering an effective dosage of dapsone to the person includes giving 75–100 milligrams of dapsone twice per day for twenty-one days.
Nasal spray delivery of dapsone liquid solution
Administering an effective dosage of dapsone via nasal spray by dispensing a liquid solution containing 5–200 milligrams of dapsone in about 50 mL into the person's nasal cavity.
Nasal spray with azithromycin and doxycycline
A nasal spray method includes a nasal spray formulation that further comprises azithromycin and doxycycline.
Inhaler apparatus delivering dapsone liquid solution
Providing an inhaler apparatus containing a liquid solution of dapsone at 75–100 mg and administering that effective dapsone dosage to a person via the inhaler.
The core inventive concept is suppressing an autoimmune reaction to COVID-19 by administering dapsone. Refinements specify a 75–100 mg twice-daily regimen, a twenty-one day course, and route/formulation narrowing to nasal spray and inhaler apparatus, with optional azithromycin and doxycycline co-ingredients.
Stated Advantages
The disclosure claims antimicrobial, anti-inflammatory, and immune-modulatory activity associated with dapsone in the COVID-19 context.
Dapsone is described as a known safety/essential medicine listing.
The disclosure states advantages related to pharmacokinetics.
The disclosure states advantages related to affordability.
Documented Applications
Suppressing an autoimmune reaction to COVID-19 in a person afflicted with COVID-19.
Treatment of acute respiratory distress syndrome (ARDS) and respiratory inflammatory complications associated with COVID-19.
Application to cytokine-storm related conditions associated with COVID-19.
Broader respiratory inflammatory disorders are referenced, including pneumonia, bronchitis, and COPD.
Other referenced conditions include seasonal/perennial rhinitis, nasal polyposis, infectious sinusitis, Crohn's disease, ulcerating colitis, and graft versus host disease.
Interested in licensing this patent?